Top

Published in:

01-07-2008 | Original Paper

Serum Prolidase and IGF-1 as Non-invasive Markers of Hepatic Fibrosis During Four Different Periods After Bile-duct Ligation in Rats

Authors: Orhan Tarçın, Nursal Gedik, Berna Karakoyun, Veysel Tahan, Gagan Sood, Çiğdem Çelikel, Nurdan Tözün

Published in: Digestive Diseases and Sciences | Issue 7/2008

Abstract

Aim Our aim was to study the correlation of serum prolidase and insulin like growth factor-1 to liver collagen and assess their utility as markers of fibrosis during four different periods of hepatic injury and fibrosis after bile-duct ligation in rats. Methods Forty-eight Wistar albino rats were included in the study and divided into six groups. Seven rats served as the control group (Control), while seven rats had a sham operation (Sham group). Thirty-four rats underwent bile-duct ligation. Bile-duct ligated (BDL) animals were sacrificed at the end of the first week (Group 1; n = 8), second week (Group 2; n = 8), third week (Group 3; n = 9), or fourth week (Group 4; n = 9) after BDL. Liver collagen, liver prolidase, and serum prolidase and IGF-I, were determined. Results There was a positive correlation between liver collagen and serum prolidase (r_s: 0.843, P < 0.001) levels and a negative correlation among liver collagen and serum IGF-1 levels (r_s: −0.667, P < 0.001). The peak levels of liver collagen and serum prolidase were reached in the third week while the lowest levels of IGF-1 were found at the end of the third week. Conclusion Serum prolidase and IGF-1 either independently or in combination correlate with liver collagen content in hepatic fibrosis.

Knittel T, Kobold D, Piscaglia F, Saile B, Neubauer K, Mehde M, Timpl R, Ramadori G (1999) Localization of liver myofibroblasts and hepatic stellate cells in normal and diseased rat livers: distinct roles of (myo-) fibroblast subpopulations in hepatic tissue repair. Histochem Cell Biol 112:387–401PubMedCrossRef

Canbay A, Friedman S, Gores GJ (2004) Apoptosis: the nexus of liver injury and fibrosis. Hepatology 39:273–278PubMedCrossRef

Friedman SL (2003) Liver fibrosis––from bench to bedside. J Hepatol 38(Suppl 1):S38–S53PubMedCrossRef

Schuppan D, Schmid M, Somasundaram R, Ackermann R, Ruehl M, Nakamura T, Riecken EO (1998) Collagens in the liver extracellular matrix bind hepatocyte growth factor. Gastroenterology 114:139–152PubMedCrossRef

Bataller R, North KE, Brenner DA (2003) Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 37:493–503PubMedCrossRef

Afdhal NH, Nunes D (2004) Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 99:1160–1174PubMedCrossRef

Forns X, Ampurdanes S, Sanchez-Tapias JM, Guilera M, Sans M, Sanchez-Fueyo A, Quinto L, Joya P, Bruguera M, Rodes J (2001) Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. J Hepatol 35:265–271PubMedCrossRef

Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, Lefkowitch JH, Ludwig J, Okuda K (1996) The long-term pathological evolution of chronic hepatitis C. Hepatology 23:1334–1340PubMedCrossRef

Curry MP (2005) Serum markers of hepatic fibrosis. Up-to-date 2005; Online 13.1:1–12

10.

Poynard T, Munteanu M, Imbert-Bismut F, Charlotte F, Thabut D, Le Calvez S, Messous D, Thibault V, Benhamou Y, Moussalli J, Ratziu V (2004) Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 50:1344–1355PubMedCrossRef

11.

Kobayashi M, Shimizu S (1999) Cobalt proteins. Eur J Biochem 261:1–9PubMedCrossRef

12.

Bazan JF, Weaver LH, Roderick SL, Huber R, Matthews BW (1994) Sequence and structure comparison suggest that methionine aminopeptidase, prolidase, aminopeptidase P, and creatinase share a common fold. Proc Natl Acad Sci USA 91:2473–2477PubMedCrossRef

13.

Guszczyn T, Sobolewski K (2004) Deregulation of collagen metabolism in human stomach cancer. Pathobiology 71:308–313PubMedCrossRef

14.

Brosset B, Myara I, Fabre M, Lemonnier A (1988) Plasma prolidase and prolinase activity in alcoholic liver disease. Clin Chim Acta 175:291–295PubMedCrossRef

15.

Abraham P, Wilfred G, Ramakrishna B (2000) Plasma prolidase may be an index of liver fibrosis in the rat. Clin Chim Acta 295:199–202PubMedCrossRef

16.

Kaymaz O, Gultepe GM, Avsar K (1999) Serum prolidase activity in diagnosis of hepatic fibrosis and following of interferon therapy, and optimization of the method. XV. National Biochemistry Congress, Abstract Book. Ankara. XV National Biochemistry Congress, Abstract Book Ankara

17.

Gültepe M, Özcan A, Altin M, Öztürk G, Demirci M (1994) Evaluation of the response of hepatic fibrosis to colchicine treatment by estimating serum prolidase activity and procollagen III amino terminal propeptide levels. Turk J Med Sci 20:99–104

18.

Sara V R, Hall K (1990) Insulin-like growth factors and their binding proteins. Physiol Rev 70:591–614PubMed

19.

Schwander JC, Hauri C, Zapf J, Froesch ER (1983) Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: dependence on growth hormone status. Endocrinology 113:297–305PubMed

20.

Blomsma MC, de Knegt RJ, Dullaart RP, Jansen PL (1997) Insulin-like growth factor-I in liver cirrhosis. J Hepatol 27:1133–1138PubMedCrossRef

21.

Moller S, Juul A, Becker U, Flyvbjerg A, Skakkebaek NE, Henriksen JH (1995) Concentrations, release, and disposal of insulin-like growth factor (IGF)-binding proteins (IGFBP), IGF-I, and growth hormone in different vascular beds in patients with cirrhosis. J Clin Endocrinol Metab 80:1148–1157PubMedCrossRef

22.

Yoshida S, Nio M, Hayashi Y, Ohi R, Kawamura I, Goto T (2003) Serum insulinlike growth factor-I in biliary atresia. J Pediatr Surg 38:211–215PubMedCrossRef

23.

Kountouras J, Billing BH, Scheuer PJ (1984) Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 65:305–311PubMed

24.

Lopez-De Leon A, Rojkind M (1985) A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J Histochem Cytochem 33:737–743PubMed

25.

Myara I, Myara A, Mangeot M, Fabre M, Charpentier C, Lemonnier A (1984) Plasma prolidase activity: a possible index of collagen catabolism in chronic liver disease. Clin Chem 30:211–215PubMed

26.

Gültepe M, Bolat B, Kayadibi H, Avsar K (2005) Investigation of the analytical steps of direct prolidase enzyme activity measurement. Turk J Biochem 30:p063(099)

27.

Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, Mac Sween RN et al (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22:696–699PubMedCrossRef

28.

Afdhal NH (2004) Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis? Clin Chem 50:1299–1300PubMedCrossRef

29.

Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M, Astemborski J, Thomas DL, Moore RE, Afdhal NH (2005) Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 43:78–84PubMedCrossRef

30.

Tarcin O, Avsar K, Demirturk L, Gultepe M, Oktar BK, Ozdogan OC, Tarcin O, Baloglu H, Gurbuz AK (2003) In vivo inefficiency of pentoxifylline and interferon-alpha on hepatic fibrosis in biliary-obstructed rats: assessment by tissue collagen content and prolidase activity. J Gastroenterol Hepatol 18:437–444PubMedCrossRef

31.

Myara I, Miech G, Fabre M, Mangeot M, Lemonnier A (1987) Changes in prolinase and prolidase activity during CCl4 administration inducing liver cytolysis and fibrosis in rat. Br J Exp Pathol 68:7–13PubMed

32.

Jiang Z, You DY, Chen XC, Wu J (1992) Monitoring of serum markers for fibrosis during CCl4-induced liver damage. Effects of anti-fibrotic agents. J Hepatol 16:282–289PubMedCrossRef

33.

Shahin M, Schuppan D, Waldherr R, Savolainen ER, Zalpur F, Rahman HM, el Sahly AM, Abdel Razek SM, el Ruby O, Seitz HK (1995) Circulating enzyme activities of collagen turnover and undulin in patients with various degrees of schistosomiasis and alcoholic liver cirrhosis. Hepatogastroenterology 42:22–26PubMed

34.

Zuyderhoudt FM, Brugman AM, Smit JJ, de Jong L (1985) Plasma prolidase in the rat: no index of liver fibrosis. Clin Chem 31:662PubMed

35.

Miltyk W, Karna E, Wolczynski S, Palka J (1998) Insulin-like growth factor I-dependent regulation of prolidase activity in cultured human skin fibroblasts. Mol Cell Biochem 189:177–183PubMedCrossRef

36.

Vyzantiadis T, Theodoridou S, Giouleme O, Harsoulis P, Evgenidis N, Vyzantiadis A (2003) Serum concentrations of insulin-like growth factor-I (IGF-I) in patients with liver cirrhosis. Hepatogastroenterology 50:814–816PubMed

37.

Kratzsch J, Blum WF, Schenker E, Keller E (1995) Regulation of growth hormone (GH), insulin-like growth factor (IGF)I, IGF binding proteins -1, -2, -3 and GH binding protein during progression of liver cirrhosis. Exp Clin Endocrinol Diabetes 103:285–291PubMedCrossRef

38.

Wu YL, Ye J, Zhang S, Zhong J, Xi RP (2004) Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis. World J Gastroenterol 10:2740–2743PubMed

39.

Sheppard MS, Minuk GY, Bhaumick B, Bala RM (1987) Insulin-like growth factors (IGF) in liver disease: differential changes of IGF-I and IGF-II. Clin Invest Med 10:49–53PubMed

Title: Serum Prolidase and IGF-1 as Non-invasive Markers of Hepatic Fibrosis During Four Different Periods After Bile-duct Ligation in Rats
Authors: Orhan Tarçın
Nursal Gedik
Berna Karakoyun
Veysel Tahan
Gagan Sood
Çiğdem Çelikel
Nurdan Tözün
Publication date: 01-07-2008
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 7/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-007-0073-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2008

Effect of Some Natural Products Either Alone or in Combination on Gastritis Induced in Experimental Rats

Simvastatin Attenuates Trinitrobenzene Sulfonic Acid-Induced Colitis, but Not Oxazalone-Induced Colitis

Independent Predictors of Steatohepatitis and Fibrosis in Asian Indian Patients with Non-Alcoholic Steatohepatitis

Yoghurts Containing Probiotics Reduce Disruption of the Small Intestinal Barrier in Methotrexate-Treated Rats

The Short-Term Effects of Different Doses of Dexamethasone on the Numbers of some Bacteria in the Ileum

Atorvastatin Does Not Improve Liver Biochemistries or Mayo Risk Score in Primary Biliary Cirrhosis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials